Alzheimer's disease

Author(s): Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, et al.

Abstract

An estimated 24 million people worldwide have dementia, the majority of whom are thought to have Alzheimer's disease. Thus, Alzheimer's disease represents a major public health concern and has been identified as a research priority. Although there are licensed treatments that can alleviate symptoms of Alzheimer's disease, there is a pressing need to improve our understanding of pathogenesis to enable development of disease-modifying treatments. Methods for improving diagnosis are also moving forward, but a better consensus is needed for development of a panel of biological and neuroimaging biomarkers that support clinical diagnosis. There is now strong evidence of potential risk and protective factors for Alzheimer's disease, dementia, and cognitive decline, but further work is needed to understand these better and to establish whether interventions can substantially lower these risks. In this Seminar, we provide an overview of recent evidence regarding the epidemiology, pathogenesis, diagnosis, and treatment of Alzheimer's disease, and discuss potential ways to reduce the risk of developing the disease.

Similar Articles

Alzheimer's disease and the Amyloid-β Peptide

Author(s): Murphy MP, LeVine H

Adrenergic receptors in aging and Alzheimer's disease: Increased β2-Receptors in prefrontal cortex and hippocampus

Author(s): Kalaria RN, Andorn AC, Tabaton M, Whitehouse PJ, Harik SI, et al.

Antihypertensive medication use and risk of cognitive impairment: The Honolulu-Asia Aging Study

Author(s): Gelber RP, Ross GW, Petrovitch H, Masaki KH, Launer LJ, et al.

Antihypertensive medication use and risk of cognitive impairment: The Honolulu-Asia aging study

Author(s): Gelber RP, Ross GW, Petrovitch H, Masaki KH, Launer LJ, et al.

Epac: Defining a new mechanism for cAMP action

Author(s): Gloerich M, Bos JL

G protein beta gamma subunits

Author(s): Clapham DE, Neer EJ

Recombinant G-protein βγ-subunits activate the muscarinic-gated atrial potassium channel

Author(s): Wickman KD, Iniguez-Lluhl JA, Davenport PA, Taussig R, Krapivinsky GB, et al.

G-protein beta Gamma-subunits activate the cardiac muscarinic K+-channel via phospholipase A2

Author(s): Kim D, Lewis DL, Graziadei L, Neer EJ, Bar-Sagi D, et al.

The expanding roles of Gβγ subunits in G Protein-coupled receptor signaling and drug action

Author(s): Khan SM, Sleno R, Gora S, Zylbergold P, Laverdure JP, et al.

Binding of amyloid β peptide to β2 adrenergic receptor induces PKA-dependent AMPA receptor hyperactivity

Author(s): Wang D, Govindaiah G, Liu R, De Arcangelis V, Cox CL, et al.

Alzheimer’s disease

Author(s): Burns A, Iliffe S

Brain amyloid-β oligomers in ageing and Alzheimer’s disease

Author(s): Lesne SE, Sherman MA, Grant M, Kuskowski M, Schneider JA, et al.

The presence of sodium dodecyl sulphate-stable Aβ dimers is strongly associated with Alzheimer-type dementia

Author(s): Mc Donald JM, Savva GM, Brayne C, Welzel AT, Forster G, et al.

Locus Coeruleus, norepinephrine and Aβ peptides in Alzheimer's disease

Author(s): Ross JA, McGonigle P1, Van Bockstaele EJ

Statistical significance for genomewide studies

Author(s): Storey JD, Tibshirani R

Mechanisms of phagocytosis in macrophages

Author(s): Aderem A, Underhill DM